| WB | 1/500 - 1/2000 | Human, Mouse, Monkey |
| IF | 咨询技术 | Human, Mouse, Monkey |
| IHC | 咨询技术 | Human, Mouse, Monkey |
| ICC | 技术咨询 | Human, Mouse, Monkey |
| FCM | 1/200 - 1/400 | Human, Mouse, Monkey |
| Elisa | 1/10000 | Human, Mouse, Monkey |
| Aliases | GTBP; HSAP; p160; GTMBP; HNPCC5 |
| Entrez GeneID | 2956 |
| clone | 1D1C2 |
| WB Predicted band size | 152.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Monkey |
| Immunogen | Purified recombinant fragment of human MSH6 (AA: 217-395) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与MSH6抗体相关的参考文献摘要整理：
1. **文献名称**: "Comparative analysis of MSH6 immunohistochemical staining in colorectal cancer using different antibody clones"
**作者**: Hall G, et al.
**摘要**: 比较了两种不同克隆号(44A和EPR3945)的MSH6抗体在结直肠癌组织中的染色性能，发现EPR3945克隆的特异性更高，尤其在检测错配修复缺陷(dMMR)时假阳性率更低。
2. **文献名称**: "Automated MSH6 staining in Lynch syndrome screening: a multicenter validation study"
**作者**: Rumilla K, et al.
**摘要**: 评估了自动化免疫组化平台(如Ventana系统)使用MSH6抗体的可靠性，结果显示其与人工判读一致性达95%，支持其在Lynch综合征大规模筛查中的应用。
3. **文献名称**: "MSH6 loss correlates with poor prognosis in endometrial carcinomas"
**作者**: Kato M, et al.
**摘要**: 通过MSH6抗体检测子宫内膜癌中的蛋白表达缺失，发现MSH6阴性患者总生存期显著缩短，提示其可作为独立预后标志物。
4. **文献名称**: "Antibody selection for mismatch repair protein detection: Pitfalls of MSH6 interpretation"
**作者**: Shia J, et al.
**摘要**: 讨论了MSH6抗体在肿瘤异质性样本中可能出现的染色陷阱(如弱阳性/局灶阳性)，提出结合MLH1/PMS2结果判读可提高诊断准确性。
这些研究覆盖了抗体性能比较、自动化检测、预后关联及诊断注意事项，可为实验设计或临床诊断提供参考。
The MSH6 antibody is a crucial tool in studying the DNA mismatch repair (MMR) system, which maintains genomic stability by correcting replication errors. MSH6. a component of the MutSα heterodimer (with MSH2), recognizes base-base mismatches and small insertion/deletion loops during DNA replication. Defects in MSH6 disrupt MMR, leading to microsatellite instability (MSI), a hallmark of Lynch syndrome and subsets of sporadic cancers (e.g., colorectal, endometrial).
Clinically, MSH6 antibodies are widely used in immunohistochemistry (IHC) to detect loss of MSH6 protein expression, aiding in diagnosing Lynch syndrome and stratifying tumors for therapy. Loss of MSH6. alone or with other MMR proteins (MLH1. PMS2. MSH2), helps identify mismatch repair-deficient (dMMR) tumors, which may respond to immune checkpoint inhibitors. However, MSH6 loss can occur due to somatic mutations or epigenetic changes, necessitating correlation with genetic testing for Lynch confirmation.
In research, MSH6 antibodies facilitate studies on MMR mechanisms, carcinogenesis, and therapy resistance. Cross-reactivity and antibody validation remain critical considerations, as false negatives/positives impact diagnostic accuracy. Overall, MSH6 antibodies bridge molecular pathology and precision oncology, guiding hereditary cancer screening and treatment decisions.
×
